专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明专利

IL239448D0 Galectin-3 plasmapheresis therapy 未知
公开(公告)号：IL239448D0
公开(公告)日：2015-07-30
申请号：IL23944815
申请日：2015-06-16
申请人： ISAAC ELIAZ
IPC分类号： A61M20060101
摘要： The invention is directed to the removal of serum gal-3 from circulation by plasmapheresis, comprising at least in part donor apheresis, using gal-3 binding agents in either a fixed bed, or in a form easily removed, such as by being complexed with magnetic particles. This method, on its own, brings a sharp reduction and relief from the inflammation and fibroses that can be induced by circulating gal-3. The process may be combined with the administration of gal-3 binding agents, such as modified citrus pectin, to further lower unbound gal-3 levels, to the point where gal-3 in the tissues may be addressed. This method may also be combined with removal of TNF receptors to provide an effective treatment for cancer.

2. 发明专利

MY179044A REDUCTION OF GALECTIN-3 LEVELS BY PLASMAPHERESIS 未知
公开(公告)号：MY179044A
公开(公告)日：2020-10-26
申请号：MYPI2014001495
申请日：2012-09-28
申请人： ISAAC ELIAZ
发明人： ISAAC ELIAZ
摘要： The invention is directed to the removal of serum gal-3 from circulation by plasmapheresis using gal-3 binding agents in either a fixed bed, or in a form easily removed, such as by being complexed with magnetic particles. This method, on its own, brings a sharp reduction and relief from the inflammation and fibroses that can be induced by circulating gal-3. The process may be combined with the administration of gal-3 binding agents, such as modified citrus pectin, to further lower unbound gal-3 levels, to the point where gal-3 in the tissues may be addressed. This method may also be combined with removal of TNF receptors to provide an effective treatment for cancer.

3. 发明专利

MY168406A GALECTIN-3 PLASMAPHERESIS THERAPY 未知
公开(公告)号：MY168406A
公开(公告)日：2018-11-07
申请号：MYPI2015001648
申请日：2013-12-27
申请人： ISAAC ELIAZ
发明人： ISAAC ELIAZ
IPC分类号： A61M1/34 , A61P35/00
摘要： The invention is directed to the removal of serum gal-3 from circulation by plasmapheresis, comprising at least in part donor apheresis, using gal-3 binding agents in either a fixed bed, or in a form easily removed, such as by being complexed with magnetic particles. This method, on its own, brings a sharp reduction and relief from the inflammation and fibroses that can be induced by circulating gal-3. The process may be combined with the administration of gal-3 binding agents, such as modified citrus pectin, to further lower unbound gal-3 levels, to the point where gal-3 in the tissues may be addressed. This method may also be combined with removal of TNF receptors to provide an effective treatment for cancer.

4. 发明专利

MX355213B REDUCCION DE LOS NIVELES DE GALECTINA-3 POR PLASMAFERESIS. 未知
公开(公告)号：MX355213B
公开(公告)日：2018-04-10
申请号：MX2014006620
申请日：2012-09-28
申请人： ISAAC ELIAZ
发明人： ISAAC ELIAZ
IPC分类号： A61M1/36 , A61M1/34 , C07K16/18 , G01N33/53
摘要： La presente invención se refiere a una molécula de unión a galectina-3 (gal-3) para usarse en un método de tratamiento (a) cáncer; o (b) fibrosis; o (c) inflamación dañina o nociva en un mamífero en donde el mamífero es respectivamente (a) en necesidad de la inhibición del crecimiento o diseminación del cáncer mediado, al menos en parte, por gal-3; o (b) en necesidad de la inhibición del desarrollo o extensión de la fibrosis mediada por gal-3; o (c) en necesidad de la inhibición de la inflamación mediada por gal-3; el método que comprende: realizar plasmaféresis en la sangre de un mamífero en necesidad de la reducción de los niveles de circulación o circulantes de gal-3 para reducir los niveles circulantes de gal-3 activa, en donde la plasmaféresis se realiza para remover selectivamente gal-3 por contacto con la molécula de unión a gal3, de modo que por lo menos diez por ciento de la gal-3 circulante en el suero de tal individuo se remueve mediante la plasmaféresis; en donde la molécula de unión a gal-3 comprende un anticuerpo de unión a gal-3 o pectina cítrica modificada (MCP).

5. 发明专利

IL232323A Reduction of galectin-3 levels by plasmapheresis 未知
公开(公告)号：IL232323A
公开(公告)日：2015-08-31
申请号：IL23232314
申请日：2014-04-29
申请人： ISAAC ELIAZ
IPC分类号： G01N20060101
摘要： A galectin-1, 9, 2, 4, 5, 6, 7, 8, 10, 11, 12, 13, 14 or 15 binding molecule for use in a method of treating a condition in a mammal mediated at least in part by active said galectin in the blood, comprising: selecting a mammal in need of reduction of circulating levels of said galectin; and conducting plasmapheresis on the blood of said mammal to reduce circulating levels of active said galectin, wherein said plasmapheresis is conducted so as to selectively remove said galectin by contact with said galectin binding molecule, such that at least ten percent of the circulating said galectin in the serum of that individual is removed by said plasmapheresis.

6. 发明专利

MY179276A GALECTIN-3 PLASMAPHERESIS THERAPY 未知
公开(公告)号：MY179276A
公开(公告)日：2020-11-03
申请号：MYPI2016002208
申请日：2013-12-27
申请人： ISAAC ELIAZ
发明人： ISAAC ELIAZ
IPC分类号： A61K45/06 , A61K35/16 , A61M1/34 , A61M1/36
摘要： The invention is directed to the removal of serum gal-3 from circulation by plasmapheresis, comprising at least in part donor apheresis, using gal-3 binding agents in either a fixed bed, or in a form easily removed, such as by being complexed with magnetic particles. This method, on its own, brings a sharp reduction and relief from the inflammation and fibroses that can be induced by circulating gal-3. The process may be combined with the administration of gal-3 binding agents, such as modified citrus pectin, to further lower unbound gal-3 levels, to the point where gal-3 in the tissues may be addressed. This method may also be combined with removal of TNF receptors to provide an effective treatment for cancer.

7. 发明专利

NZ624601A Reduction of galectin-3 levels by plasmapheresis 未知
公开(公告)号：NZ624601A
公开(公告)日：2014-09-26
申请号：NZ62460112
申请日：2012-09-28
申请人： ISAAC ELIAZ
发明人： ELIAZ ISAAC
IPC分类号： G01N33/53
摘要： The disclosure relates to the removal of serum gal-3 from circulation by plasmapheresis using gal-3 binding agents in either a fixed bed, or in a form easily removed, such as by being complexed with magnetic particles. This method, on its own, brings a sharp reduction and relief from the inflammation and fibroses that can be induced by circulating gal-3. The process may be combined with the administration of gal-3 binding agents, such as modified citrus pectin, to further lower unbound gal-3 levels, to the point where gal-3 in the tissues may be addressed. This method may also be combined with removal of TNF receptors to provide an effective treatment for cancer. Particularly disclosed is the use of a gal-3 binding molecule in the preparation of a medicament for treating a condition in a mammal mediated at least in part by active galectin-3 in the blood, wherein the medicament is formulated for conducting plasmapheresis on blood obtained from the mammal; and wherein the medicament selectively removes galectin-3 (gal-3) by contact with said gal-3 binding molecule of the medicament, such that at least ten percent of the gal-3 in serum of the mammal is removed by said plasmapheresis.

8. 发明专利

IL98003D0 METHOD AND PRODUCT FOR PROMOTING HAIR GROWTH AND TREATING SKIN CONDITIONS 未知
公开(公告)号：IL98003D0
公开(公告)日：1992-06-21
申请号：IL9800391
申请日：1991-04-30
申请人： SHMUEL GONEN , ISAAC ELIAZ
IPC分类号： A61K20060101 , A61K

9. 发明授权

US08426567B2 Method for enhancing mammalian immunological function 有权
标题翻译：增强哺乳动物免疫功能的方法
公开(公告)号：US08426567B2
公开(公告)日：2013-04-23
申请号：US11485955
申请日：2006-07-14
申请人： Isaac Eliaz
发明人： Isaac Eliaz
IPC分类号： C08B37/06 , C08B37/04 , C07H1/00 , A61K31/732 , A61K31/734
CPC分类号： A61K36/28 , A61K31/734 , A61K36/16 , A61K36/537 , A61K36/8962 , A61K2300/00
摘要： Low molecular weight modified pectin, particularly modified citrus pectin (MCP), and/or low molecular weight modified alginate is useful in a composition for stimulating the immune response of a mammal, particularly a human. Modified pectin and/or modified alginate is administered in a composition in an amount sufficient to modulate, support, enhance or extend an immune response, particularly to an individual having an inadequate or reduced immune function. Stimulation of an immune response is evidenced by stimulation of cell-mediated immune function, humoral immune function, phagocytic function of mononuclear macrophages, and NK cell activity. The composition also may comprise well known pharmacologically acceptable agents, such as sulfured amino acids, cilantro, garlic, minerals, and herbs.
摘要翻译：低分子量改性果胶，特别是改性柑橘果胶（MCP）和/或低分子量改性藻酸盐可用于刺激哺乳动物特别是人的免疫反应的组合物中。经修饰的果胶和/或修饰的藻酸盐以足以调节，支持，增强或延长免疫应答的量的组合物施用，特别是对具有不足或降低的免疫功能的个体。通过刺激细胞介导的免疫功能，体液免疫功能，单核巨噬细胞的吞噬功能和NK细胞活性来证明刺激免疫应答。组合物还可以包含众所周知的药理学上可接受的试剂，例如硫化氨基酸，香菜，大蒜，矿物质和草药。

10. 发明申请

US20070167395A1 Compositions and methods for treating diabetes 审中-公开
标题翻译：治疗糖尿病的组合物和方法
公开(公告)号：US20070167395A1
公开(公告)日：2007-07-19
申请号：US11332237
申请日：2006-01-17
申请人： Isaac Eliaz
发明人： Isaac Eliaz
IPC分类号： A61K31/732 , A61K31/729
CPC分类号： A61K31/729 , A61K31/732
摘要： Low molecular weight modified alginate and/or low molecular weight modified pectin, particularly modified citrus pectin (MCP), is useful in a composition for the treatment of diabetes, when administered to a diabetic individual. For instance, a composition comprising MCP is administered to an individual in an amount sufficient to reduce a parameter associated with diabetes severity, particularly levels of total blood glucose or triglyceride. The composition also may comprise well known pharmacologically acceptable agents, such as sulfured amino acids, cilantro, garlic, minerals, and herbs.
摘要翻译：低分子量改性藻酸盐和/或低分子量改性果胶，特别是经修饰的柑橘果胶（MCP）可用于治疗糖尿病的组合物，当给予糖尿病个体时。例如，包含MCP的组合物以足以减少与糖尿病严重性，特别是总血糖或甘油三酸酯水平相关的参数的量给予个体。组合物还可以包含众所周知的药理学上可接受的试剂，例如硫化氨基酸，香菜，大蒜，矿物质和草药。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式